Analysis of Crizotinib Price Forecast and Medical Insurance Reimbursement in 2024

Crizotinib (Crizotinib, a drug with significant efficacy in the anti-cancer field, brings new hope to patients with non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT) with its unique inhibitory effect on ALK and ROS 1. As a highly effective kinase inhibitor, it can precisely block the growth signals of tumor cells.

For many patients, the price of crizotinib has been a focus of concern. Currently, crizotinib capsules sold under the brand "XALKORI" in the domestic market are available in two specifications: 250mg*60 capsules and 200mg*60 capsules. The price of each box is quite high, reaching more than 10,000 yuan. Fortunately, for patients who meet the indications, the national medical insurance provides certain reimbursement support, reducing their financial burden. At the same time, in overseas markets, the price of crizotinib also showed a similar trend. Despite the impact of exchange rate fluctuations, the selling price of each box remains at more than 10,000 yuan. However, for patients looking for a more affordable option, generic drugs may be an option worth considering.

Generic drugs are drugs produced by other pharmaceutical companies according to the same standards and specifications after the patent protection period of the original drug has expired. Currently, there are already some relatively low-priced generics of crizotinib available in overseas markets. For example, a box of generic drugs produced by Bangladesh and Laos pharmaceutical factories with a specification of 250mg*60 pills is only about 2,000 yuan (the price may fluctuate due to exchange rates).

Therefore, patients should refer to the actual selling price when purchasing, and carefully choose drug purchasing channels to ensure the quality and safety of the drugs.